Why the U.S. Drug Pricing System Is Structurally Adversarial to Buyers

The fundamental problem is not a single bad actor, but a system engineered for cost leakage. As Owen Tripp, CEO of Included Health, put it bluntly, current drug price mechanisms work against buyers. This isn't a minor inefficiency; it's the intended design. The system operates as a segmented, opaque machine that systematically extracts value from payers, from insurers to employers, through pervasive price dispersion and a lack of transparency.

The core mechanism is price dispersion. Pharmaceutical manufacturers routinely charge different prices to different purchasers for the same product. This practice thrives where suppliers have market power and buyers vary in their sensitivity to price. As a 2000 HHS conference paper noted, variation in price sensitivities across purchasers... often leads to a wide spectrum of prices for a given pharmaceutical product. The result is a fragmented marketplace where the "best price" is a moving target, and the actual cost to any single buyer is determined by their relative market power and negotiating leverage.

This fragmentation creates the major cost leakage. The largest discounts for private purchasers are typically 12 to 17 percentage points below the 'best price' that manufacturers publicly tout. In other words, the headline price is often a fiction. The real cost to a buyer is negotiated in the shadows, buried in complex rebate structures and confidential contracts. This isn't just about a few percentage points; it's about a structural gap that consistently erodes the purchasing power of payers, making the system inherently adversarial to those footing the bill.

The Structural Drivers: Patents, Innovation, and the Access Gap

The system's adversarial nature is not accidental; it is sustained by powerful economic and policy forces. At its core is a trade-off: robust patent protection and the high cost of research and development are designed to incentivize innovation. Yet this very structure creates the conditions for wide price dispersion. As a 2000 HHS conference paper explained, variation in price sensitivities across purchasers... often leads to a wide spectrum of prices for a given pharmaceutical product, a dynamic amplified by patent power and low production costs. The result is a marketplace where the "best price" is a myth, and the real cost to any buyer is a function of their negotiating power, not a fixed market value.

This tension is now being tested by an unprecedented surge in demand for a new class of blockbuster drugs. Medications like Ozempic and Wegovy, part of the GLP-1 agonist family, have exploded in popularity for weight management. The demand is massive and unmanaged, creating a new, expensive category that payers and employers are ill-equipped to handle. As Owen Tripp, CEO of Included Health, noted, this is a huge concern for employers because these drugs are super expensive, and there's a lot of demand for them. The cost is staggering; for a company like ArcBest, Ozempic is already its fourth-costliest drug, and the avalanche of demand is just beginning.

This explosive demand is straining traditional coverage models to the breaking point. Employers, caught between the clinical promise of these drugs and their unsustainable price tags, are being forced into difficult rationing decisions. Some are already requiring employees to attempt other, cheaper treatments before approving coverage for these expensive injectables. This shift toward prior authorization and step therapy is a direct response to the unmanaged cost center these drugs represent. It signals a system under pressure, where the initial promise of innovation is colliding with the harsh arithmetic of scale, and buyers are left to navigate a new, more restrictive landscape.

The Transparency Deficit and Evolving Models

The system's core weakness is not just opaque pricing, but the absence of a clear benchmark for actual acquisition cost. For decades, the industry has relied on flawed standards like Average Wholesale Price (AWP), which was originally based on survey data from pharmaceutical wholesalers but has long been recognized as a poor proxy for real cost. The result is a supply chain operating in a fog, where the "best price" touted by manufacturers is a fiction, and the actual cost to any buyer is a function of their negotiating power, not a fixed market value. This lack of transparency is the foundational problem that new models must address.

In response, the industry has developed a suite of innovative payment models. These include health outcomes contracts and subscription pricing, which aim to tie payments to real-world performance rather than a static list price. The logic is sound: if a drug fails to deliver promised benefits, the payer should not be fully on the hook. As evidence shows, new technology for monitoring patients and gathering health data has accelerated the use of value-based contracting, and executives from major biopharma companies have embraced these arrangements. The goal is to align incentives and improve patient access.

Yet these models often add complexity without resolving the fundamental issue of opaque initial pricing and discounting. The very data needed to measure outcomes-patient records, treatment adherence, clinical results-is frequently siloed and difficult to share across the fragmented healthcare ecosystem. This creates significant data-sharing challenges and operational hurdles that can stall or complicate these contracts. More broadly, they operate on top of the existing, broken system. A health outcomes contract for a blockbuster drug still begins with a negotiated, confidential price that is likely far above the true acquisition cost. The model may mitigate risk downstream, but it does nothing to fix the upstream cost leakage that defines the system.

The bottom line is that these new models are incremental fixes to a structural problem. They represent an evolution in financial engineering, not a revolution in transparency. Until there is a widely accepted, comprehensive benchmark for actual acquisition cost across the supply chain, the system will continue to work against buyers. The promise of value-based contracts is real, but their potential is constrained by the same opacity that makes the entire pricing architecture adversarial.

Catalysts and Risks: Policy, Gaming, and the Innovation Trade-Off

The current equilibrium is precarious, sustained by a fragile balance between powerful incentives and systemic opacity. The primary catalyst for change is the looming threat of a Most-Favored Nation (MFN) pricing policy. This approach, which would peg U.S. drug prices to the lowest level paid by comparable countries, is easily gamed. As research shows, drug companies and their overseas customers could create the appearance of higher prices overseas by agreeing to confidential rebates-a practice already common abroad. This loophole means the policy could compress U.S. prices in name only, while manufacturers maintain low net prices through off-book deals, leaving the fundamental cost leakage intact.

The bigger risk, however, is not just policy failure but policy backlash. Any drastic price compression could inadvertently undermine the financial incentives that drive future drug innovation. The U.S. market is the primary engine for global pharmaceutical profits, accounting for about 70% of global pharmaceutical profits. If firms face deep cuts here, they may pull out of weaker overseas markets instead, preserving their U.S. revenue but reducing access elsewhere. More critically, the promise of new medicines could be jeopardized. As one analysis warns, shifting to a European pricing model in the U.S. would lead to shorter, less healthy lives for Americans, adding up to a loss of trillions. The trade-off is stark: immediate cost savings for payers versus a long-term erosion of the innovation pipeline.

Meanwhile, technological forces are adding a new layer of complexity. The rise of AI and data analytics offers a path toward greater cost transparency, potentially empowering buyers with better benchmarks. Yet these same tools also increase the operational burden of managing new, segmented payment models. As Owen Tripp of Included Health noted, the system's complexity is overwhelming for the average patient. We throw out them in medicine, in medicine and, and in healthcare and insurance, and they need about 5000 words for their daily lives. AI can help navigate this maze, but it also enables more intricate, data-intensive contracts that require significant administrative overhead. The net effect may be a system that is more transparent in theory but more complex and costly to manage in practice.

The bottom line is that disruption is likely, but its outcome is uncertain. Policy changes risk breaking the innovation engine, while technological advances risk deepening the administrative quagmire. The system's stability hinges on finding a middle path-one that curbs egregious cost leakage without torpedoing the incentives that deliver tomorrow's breakthroughs. For now, that balance remains elusive.